Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
- EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results
- Principal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and explain its potential for revolutionizing cancer treatment
COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place on November 8 at 11:30 a.m. EST.
In this 30-minute-long event, Professor Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion’s personalized cancer vaccines are trying to meet. After summarizing the promising results reported in the EVX-01 Phase 1 clinical trial, Adnan will dive into Evaxion’s latest EVX-01 Phase 2 clinical update and how these appear to confirm the benefits previously observed for this innovative immunotherapy. In the end, a Q&A session will be held for anyone who wants to learn more about this study and its underlying technology.
Evaxion’s Chief Executive Officer, Christian Kanstrup, commented: “‘This latest clinical update stands as a testament to Evaxion’s unwavering dedication to transforming patients’ lives through innovative and targeted immunotherapies. Despite initial skepticism surrounding our pioneering work in personalized cancer vaccines, we are now reaping consistently positive outcomes that we believe hold the promise to change the lives of melanoma patients.” Reflecting on how these results may impact the oncology field in the near future, Christian added, “‘We firmly believe that our AI-Immunology™ platform has the potential to spearhead a revolution in immuno-oncology, extending far beyond melanoma and positively touching the lives of countless individuals.”
To learn more about the clinical impact of Evaxion’s innovative EVX-01 vaccine and gain understanding of how personalized cancer vaccines can revolutionize the field of immuno-oncology, please register by following this link.
About EVX-01 Phase 1 Clinical Trial
The open-label, single-arm, single-center Phase 1 study was conducted in collaboration with DTU, SSI, the Center for Genomic Medicine at Rigshospitalet, and CCIT-DK. The study aimed to assess the safety and efficacy of the EVX-01 vaccine in combination with anti-PD1 (pembrolizumab or Nivolumab) in patients with metastatic melanoma. The design consisted of multiple 15-27mer peptides comprising one or more patient-specific neoantigens formulated with the novel liposomal adjuvant CAF®09b to potentiate immune responses. The primary objective was to evaluate the safety and tolerability of the combination of EVX-01 and a checkpoint inhibitor. Additional information can be accessed under clinical trial ID NCT03715985.
About EVX-01 Phase 2 Clinical Trial
EVX-01 is Evaxion’s lead clinical asset and constitutes a peptide-based personalized cancer vaccine. The Phase 2 clinical study is a self-sponsored open-label, single-arm, multi-center trial carried out in collaboration with Merck Sharp & Dohme LLC, and together with leading principal investigators and research centers from Italy and Australia aims at evaluating the efficacy and safety of EVX-01 vaccination in combination with anti-PD1 treatment (pembrolizumab) in treatment-naive patients with metastatic or unresectable malignant stage III or IV melanoma. More information can be accessed under clinical trial ID NCT05309421.
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Havila Kystruten AS: Fourth quarter 2023 accounts28.2.2024 22:24:49 CET | Press release
Summary The company has completed its first quarter with full operation of all four ships. Revenue in the fourth quarter was MNOK 249. Due to late clarification on the delivery of the last two ships, the revenue side is somewhat lower than if the pre-sale had started earlier. The last quarter of 2023 ended with an average fleet occupancy of 60%, an average cabin rate (ACR) of NOK 3,100 and a utilization rate of 1.8 per cabin. Occupancy and average price per cabin are higher than the fourth quarter of 2022, but are somewhat lower than the third quarter due to lower demand in the autumn and winter months. EBITDA was negative by MNOK 33.2 in the fourth quarter and MNOK 179 for the full year. Operating costs amounted to MNOK 283 in the fourth quarter and are mainly ordinary operating costs for operating four ships. Some of the operating costs are related to the number of passengers, while the largest cost items are not significantly affected by occupancy. MNOK 18 relates to extraordinary m
Havila Kystruten AS: Regnskap for fjerde kvartal 202328.2.2024 22:24:49 CET | Pressemelding
Sammendrag Selskapet har gjennomført sitt første kvartal med full drift av alle fire skip. Inntektene utgjorde i fjerde kvartal MNOK 249. Som følge av sen avklaring på levering av de to siste skipene, er inntektssiden noe lavere enn om forhåndssalget hadde startet før. Siste kvartal i 2023 endte med et gjennomsnittlig belegg for flåten på 60%, en gjennomsnittlig lugarrate (ACR) på NOK 3 100 og en utnyttelsesgrad på 1,8 per lugar. Belegg og gjennomsnittspris per lugar er høyere enn fjerde kvartal 2022, men er noe lavere enn tredje kvartal som følge av lavere etterspørsel i høst- og vintermånedene. EBITDA var negativ med MNOK 33,2 i fjerde kvartal og MNOK 179 for hele året. Driftskostnadene utgjør MNOK 283 i fjerde kvartal og er hovedsakelig ordinære driftskostnader for drift av fire skip. Deler av driftskostnadene er knyttet til antall passasjerer, mens de største kostnadspostene ikke er vesentlig påvirket av belegg. MNOK 18 gjelder ekstraordinære kostnader til markedsføring for å sikre
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update28.2.2024 22:15:25 CET | Press release
- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update. “2024 is poised to be a transformational year for Merus.
Magnus Nicolin proposed as new Chairman of Hexatronic Group28.2.2024 21:15:00 CET | Press release
Press release February 28, 2024 Gothenburg, Sweden Magnus Nicolin proposed as new Chairman of Hexatronic Group The Nomination Committee of Hexatronic Group AB (publ) has informed the company that it intends to propose Magnus Nicolin for election as Chairman of the Board of Hexatronic, at the Annual General Meeting that will be held on May 7, 2024. Anders Persson has informed the Nomination Committee that he intends to step down from his position as Chairman if the Nomination Committee finds a suitable candidate for the position. The Nomination Committee has now announced that Magnus Nicolin is available as Chairman and that Anders Persson has informed the Nomination Committee that he therefore will not be available for re-election at the Annual General Meeting. The Nomination Committee therefore intends to propose Magnus Nicolin as new Chairman of the Board of Hexatronic. Until the date of the Annual General Meeting, Anders Persson will continue to lead the Board’s work. Magnus Nicolin
Magnus Nicolin föreslås som ny styrelseordförande i Hexatronic Group28.2.2024 21:15:00 CET | Pressemelding
Pressmeddelande 28 februari, 2024 Göteborg Sverige Magnus Nicolin föreslås som ny styrelseordförande i Hexatronic Group Valberedningen i Hexatronic Group AB (publ) har informerat bolaget att de har för avsikt att föreslå att Magnus Nicolin ska väljas till ny styrelseordförande vid årsstämman den 7 maj 2024. Anders Persson har informerat valberedningen, att förutsatt att valberedningen hittar en ny kandidat till posten som styrelseordförande, ställer han sin plats till förfogande. Valberedningen har nu meddelat att Magnus Nicolin står till förfogande som ny styrelseordförande och att Anders Persson har meddelat att han därmed inte är tillgänglig för omval vid årsstämman. Valberedningen avser därför att föreslå Magnus Nicolin som ny styrelseordförande för Hexatronic. Anders Persson kommer att fortsätta att leda styrelsens arbete fram till och med årsstämman. Magnus Nicolin har omfattande internationell erfarenhet och är idag styrelseordförande i Munters Group AB (publ) samt styrelseledam